In a research note issued to investors, David Steinberg at Jefferies Reiterated their Buy rating on Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). The analyst placed a $19.00 price target on the stock which indicates a 25.50% upside to the last closing price. In the year following Steinberg’s ratings, the stocks covered yield an average return of 21.2% according to TipRanks.com. In the past year 24 out of 35 recommendations or 69% were successful.
Wall Street sell-side analysts have placed a $18 one year price target on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). This is the consensus average based on 4 firms who have recently issued reports on the equity.
The average recommendation is the arithmetical average of the individual analyst ratings contributed by sell-side research to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 represents a Strong Buy and 5 represents a Strong Sell,Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is ranked 1.25 based on 4 broker recommendations. Of the 4 analyst estimates, the most bullish sees the stock reaching $19 within the next 12 months while the most bearish analyst sees the stock at $17 within the year.
Taking a look at the long term growth prospects of the stock, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.
According to analysts, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is expected to report earnings per share for the current fiscal quarter of $-0.14. This is the consensus mean estimate based on the individual covering sell-side firm’s reported numbers. The company last reported earnings for the period ending on 2015-03-31 of $-0.04.